The Interaction of Temozolomide with Blood Components Suggests the Potential Use of Human Serum Albumin as a Biomimetic Carrier for the Drug

The interaction of temozolomide (TMZ) (the main chemotherapeutic agent for brain tumors) with blood components has not been studied at the molecular level to date, even though such information is essential in the design of dosage forms for optimal therapy. This work explores the binding of TMZ to hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubio-Camacho, Marta, Encinar, José A., Martínez-Tomé, María José, Esquembre, Rocío, Mateo, C. Reyes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408562/
https://www.ncbi.nlm.nih.gov/pubmed/32659914
http://dx.doi.org/10.3390/biom10071015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408562/
https://www.ncbi.nlm.nih.gov/pubmed/32659914
http://dx.doi.org/10.3390/biom10071015

Ejemplares similares